首页> 外国专利> New isolated DNA sequences, used for increasing production of the anticholesterol agent lovastatin, encode proteins involved in lovastatin biosynthesis in Monascus

New isolated DNA sequences, used for increasing production of the anticholesterol agent lovastatin, encode proteins involved in lovastatin biosynthesis in Monascus

机译:用于提高抗胆固醇药物洛伐他汀产量的新分离DNA序列编码红曲霉中洛伐他汀生物合成中涉及的蛋白质

摘要

Isolated DNA molecules (a) have any of the sequences (all reproduced) (1; 226 nucleotides (nt)), a lovastatin probe; (2; 9818 nt), mkA; (3; 8081 nt), mkB; (4; 1717 nt), mkC; (5; 792 nt), mkD; (6; 1228 nt), mkE; (7; 1425 nt), mkF; (8; 3356 nt), mkG; (9; 1464 nt), mkH; or (10; 2148 nt), mkI; or (b) are sequences that hybridize to (a) under stringent conditions. Independent claims are also included for the following: (1) shuttle vector containing the new molecules; (2) isolated DNA sequences (all reproduced) that are the cDNAs corresponding to genomic sequences (2)-(10); (3) shuttle vectors that contain the cDNA of (2); (4) cells transformed with at least one sequence (2)-(10) or the new cDNA; (5) method for increasing production of lovastatin (I) by transforming a (I)-producing cell with at least one of (2)-(10) or the corresponding cDNA; (6) method for producing an inhibitor (X) of HMG-CoA reductase by culturing an (X)-producing cell that has been transformed with any of (2), (3), (6) and (7), or the corresponding cDNA; (7) isolated DNA that (i) encodes the proteins (all sequences reproduced) (11; 3075 amino acids (aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa); or (18; 543 aa) or (ii) can hybridize to (i) under stringent conditions; and (8) expression vector that contains the DNA of (7). ACTIVITY : Hypotensive; Antidiabetic; Antilipemic; Antifungal. No details of tests for these activities are given. MECHANISM OF ACTION : HMG-Co reductase Inhibitor.
机译:分离的DNA分子(a)具有任何序列(全部已复制)(1; 226个核苷酸(nt)),是洛伐他汀探针; (2; 9818 nt),mkA; m / z。 (3; 8081 nt),mkB; (4; 1717 nt),mkC; m / z。 (5; 792 nt),mkD; m / z。 (6; 1228 nt),mkE; (7; 1425 nt),mkF; m / z。 (8; 3356 nt),mkG; m / z。 (9; 1464 nt),mkH; m / H。或(10; 2148 nt),mkI; (b)是在严格条件下与(a)杂交的序列。还包括以下方面的独立权利要求:(1)包含新分子的穿梭载体; (2)分离的DNA序列(全部复制),它们是与基因组序列(2)-(10)相对应的cDNA。 (3)含有(2)的cDNA的穿梭载体; (4)用至少一种序列(2)-(10)或新cDNA转化的细胞; (5)通过用(2)-(10)或相应的cDNA中的至少一种转化产生(I)的细胞来增加洛伐他汀(I)产生的方法; (6)通过培养已经用(2),(3),(6)和(7)中任一项或第(7)项转化的(X)产生细胞来生产HMG-CoA还原酶抑制剂(X)的方法。相应的cDNA; (7)分离的DNA,其(i)编码蛋白质(所有复制的序列)(11; 3075个氨基酸(aa)); (12; 2547 aa); (13; 524 aa); (14; 263 aa); (15; 360 aa); (16; 413 aa); (28; 1052 aa); (17; 455 aa);或(18; 543 aa)或(ii)可在严格条件下与(i)杂交;或(8)含有(7)的DNA的表达载体。活动:低血压;抗糖尿病抗血脂;抗真菌药。没有提供这些活动的测试详细信息。作用机理:HMG-Co还原酶抑制剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号